Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT02665143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02665143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
July 21, 2016
Completion date
March 30, 2021
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia